Adrenogenital Syndrome Treatment Market. The global adrenogenital syndrome treatment market is poised for substantial growth, ...

A Boulder-based company that is developing a orally-delivered drug for obesity and metabolic disorders just reached $25M in ...

Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with ...

Raymond Stevens, Structure Therapeutics CEO, joins 'Fast Money' to talk its oral GLP-1 offerings. Federal appeals court ...

Four oral glucagon-like peptide-1 receptor (GLP1R) drugs, currently under Phase III trials, are in the race for approval, ...

The proposal would "address unforeseen circumstances" with its oral fluid drug testing rule due to a lack of certified labs.

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

The FDA has accepted the NDA for paltusotine for the treatment and long-term maintenance of acromegaly in adults.

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

It is also developing the drug as a first-line alternative to complement-targeting antibodies in the APPOINT-PNH trial due to read out in January. Image Phil Taylor ...

The U.S. Department of Transportation is once again clearing up a “factual impossibility” regarding the inclusion of oral ...

Delivering biologics via oral administration represents a growing market that is expected to exhibit 35% CAGR from 2023–2028.